Table 4.
Time to recurrence rate/freedom from recurrence and disease-free survival in studies comparing different follow-up routines in colorectal cancer.
| Trial/Reference | Inclusion Years | Total Number of Pts | Number of Patients in Stage I/II/III | Colon/Rectum | Proportion Receiving ACT |
Follow-Up Time (Years) | TTR/FFR | DFS | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Kjeldsen et al. [104] | 1983–1994 | 597 | 138/293/166 | 313/284 | 0 | 5 | 68% | Recurrence risk 13% stage I, 20% stage II, 48% stage III, slightly higher in rectum than in colon | |
| Ohlsson et al. [105] | NR | 107 | 0 | 5 | 67% | Limited information provided | |||
| Mäkelä et al. [106] | 1988–1990 | 106 | 28/48/30 | 75/31 | 0 | 5 | 59% | Recurrence risk 36% stage I, 38% stage II, 50% stage III | |
| Secco et al. [107] | 1988–1996 | 358 | ?/201/137 | 0/358 | 0 | 5 | 45% | Did not separate stage I + II | |
| Schoemaker et al. [108] | 1984–1990 | 325 | 71/153/101 | 238/87 | 0 | 5 | 67% | Median number of nodes = 7 | |
| Rodriguez-Moranta et al. [109] | 1988–2001 | 259 | 0/157/102 | 194/65 | 100% | 4 | 73% | ||
| GILDA [110] | 1998–2006 | 1228 | 0/617/611 | 933/295 | 85% | 5 | 80% | 75–82% | DFS about 73% at 8 years |
| COLOFOL [111] | 2006–2010 | 2555 | 0/1352/1203 | 1671/884 | 47% | 5 | 78% | NR | 5-year cancer-specific survival stage II 93%, stage III 84% |
| FACS [112,113,114] | 2003–2009 | 1202 | 254/553/354 | 843/359 | 41% | 4.4 | 83% | Recurrence risk 16% colon, 24% rectum, 9% stage I, 16% stage II, 27% stage III |
The trials were included in a systematic review published in 2015 [115]. Three trials [116,117,118] did not provide any meaningful recurrence data. Using the same search criteria, one additional study [111] was found. Abbreviations: TTR/FFR: time to tumour recurrence/freedom from recurrence (100-recurrence rate in % as provided in the articles), DFS = disease-free survival, ACT= adjuvant chemotherapy, NR or ? = not reported.